According to DelveInsight's' estimates, Acute Respiratory Distress Syndrome Market in 7MM is expected to show positive growth, during the forecast period (2019-2032)

The Acute Respiratory Distress Syndrome Market Insights report from DelveInsight provides a thorough understanding of the Acute Respiratory Distress Syndrome Market size by treatment, epidemiology, emerging therapies, Acute Respiratory Distress Syndrome market share of the various therapies, and the current and forecasted Acute Respiratory Distress Syndrome Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.

Acute Respiratory Distress Syndrome: An Overview
Acute respiratory distress syndrome (ARDS) is a severe lung condition that causes low blood oxygen. People who develop ARDS are usually ill due to another disease or a major injury. In ARDS, fluid builds up inside the tiny air sacs of the lungs, and surfactant breaks down. ARDS may develop over a few days, or it can get worse very quickly. Usually, the first symptom of ARDS is shortness of breath. Besides, other signs and symptoms of ARDS are low blood oxygen, rapid breathing, and clicking, bubbling, or rattling sounds in the lungs when breathing.

Download a sample copy of the Acute Respiratory Distress Syndrome report offering- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions covered in the report
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key Takeaways from Acute Respiratory Distress Syndrome Market
• The Acute Respiratory Distress Syndrome market size in seven major markets was USD 1,260 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 11.37% for the study period (2019-2032)
• The expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in the Acute Respiratory Distress Syndrome incident population.
• Upcoming therapies such as MultiStem, Zyesami (Aviptadil), and others have the potential to create a significant positive shift in the Acute Respiratory Distress Syndrome market size.
• The United States accounts for the largest Acute Respiratory Distress Syndrome market size, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.
• Among the EU5 countries, Germany had the highest Acute Respiratory Distress Syndrome market size with USD 186 million in 2021.

Acute Respiratory Distress Syndrome Epidemiology Insights
As per DelveInsight, the total Acute Respiratory Distress Syndrome incident population in the 7MM was over 887K, with the US accounting for the maximum number of cases in 2020. Among EU5 countries, Germany had the highest ARDS incident population while Spain had the lowest in 2020.

Acute Respiratory Distress Syndrome Epidemiology Segmentation in the 7MM
• Total Acute Respiratory Distress Syndrome Incident Population
• Acute Respiratory Distress Syndrome Severity-Specific Incident Population
• Acute Respiratory Distress Syndrome Incident Population by Risk Factors

Acute Respiratory Distress Syndrome Market
Despite decades of research, Acute Respiratory Distress Syndrome treatment options are limited. The mainstay of management remains supportive care with mechanical ventilation. There are only a few ARDS treatments available. Other treatment options for patients that develop ARDS include supplemental oxygen, prone positioning, and the use of paralytics, fluid management, and a technique known as positive end-expiratory pressure (PEEP) to help push fluid out of air sacs. These are used in addition to ongoing treatment for the original disease or injury. As people with ARDS are less able to fight infections in their lungs, they are more likely to develop bacterial pneumonia. Antibiotics are used to treat infections. Additionally, supportive care, such as intravenous fluids or food may be required.
Check ARDS Market Share- https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acute Respiratory Distress Syndrome Market Drivers and Barriers
The factors that are driving the Acute Respiratory Distress Syndrome market include the increase in Acute Respiratory Distress Syndrome incidence and increasing R&D activities by key pharma companies to improve the treatment landscape. Furthermore, the non-competitive landscape of the ARDS market is also boosting market growth. On the contrary, lack of awareness about the disease, misdiagnosis of ARDS, failure of trials for Acute Respiratory Distress Syndrome are among the factors that are restricting the growth of the market. In addition, the poor mechanical ventilation for Acute Respiratory Distress Syndrome management is also restraining the Acute Respiratory Distress Syndrome market growth.

Acute Respiratory Distress Syndrome Emerging Drugs

EB05: Edesa Biotech
EB05 is a monoclonal antibody that Edesa believes could regulate the overactive and dysfunctional immune response associated with ARDS. Specifically, the drug inhibits toll-like receptor 4 (TLR4) signaling - an important mediator of inflammation responsible for acute lung injury that is activated by SARS-CoV2, SARS-CoV1, and Influenza viruses. It has demonstrated safety in clinical studies and was able to block LPS-induced (TLR4 agonist) IL-6 release in humans. Given, this extensive body of evidence it is believed that EB05 could ameliorate ARDS due to Covid-19, significantly reducing ventilation rates and mortality. The company is presently discussing the design of the final Phase III protocol with the FDA.

Alteplase (Actilyse): Boehringer Ingelheim/ Genentech
Alteplase which is marketed as Actilyse by Boehringer Ingelheim in countries outside of the US and Canada is presently being evaluated in Phase II/III (TRISTARDS) to treat Covid-19 ARDS. Phase III part of TRISTARDS was initiated based on the analysis of the first part of the TRISTARDS study (Phase IIb) which supported the further development of the drug.

BIO-11006: BioMarck Pharmaceuticals
BIO-11006 is a novel patented peptide that inhibits the myristoylated alanine-rich C kinase substrate (MARCKS) protein. Phosphorylation of the MARCKS protein has been shown to stimulate cell division and movement. BIO-11006 is part of a portfolio of over 100 patented compounds owned by Biomarck. Lately, the company reported that the first patients had been treated with BIO-11006 in a Phase II clinical study for patients with ARDS.

ExoFlo (DB-001): Direct Biologics
ExoFlo (DB-001) by Direct Biologics is an extracellular signal product isolated from human bone marrow mesenchymal stem or stromal cells (BM-MSCs) that contains growth factors and extracellular vesicles including exosomes. ExoFlo provides natural bioactive signals that downregulate inflammation, direct cellular communication, and upregulate tissue repair in humans. In June 2020 the company received approval from FDA to proceed with a phase II trial under an Investigational New Drug (IND) application for the use of ExoFlo.

Get to know more information of the report- https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Acute Respiratory Distress Syndrome Market Overview at a Glance
4. Acute Respiratory Distress Syndrome Market: Future Perspective
5. Executive Summary of Acute Respiratory Distress Syndrome
6. Key Events
7. Disease Background and Overview
8. Acute Respiratory Distress Syndrome Epidemiology and Patient Population
9. Patient Journey
10. Off-Label Therapies for ARDS
11. Emerging Drugs
12. Acute Respiratory Distress Syndrome: Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Acute Respiratory Distress Syndrome Market Drivers
15. Acute Respiratory Distress Syndrome Market Barriers
16. SWOT Analysis
17. Reimbursement and Market Access
18. Unmet Needs
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Acute Respiratory Distress Syndrome Market Report Scope
• The report covers the descriptive overview of Acute Respiratory Distress Syndrome, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
• Comprehensive insight has been provided into the Acute Respiratory Distress Syndrome epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute Respiratory Distress Syndrome is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Acute Respiratory Distress Syndrome market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acute Respiratory Distress Syndrome market.

Acute Respiratory Distress Syndrome Market Report Highlights
• The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the Acute Respiratory Distress Syndrome market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Acute Respiratory Distress Syndrome. The launch of emerging therapies will significantly impact the Acute Respiratory Distress Syndrome market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

For any query or doubt, visit here- https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.